ArticleCell stem cell2021
Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Cell stem cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 148 citations in OpenAlex.
- Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026Review
- Can natural killer cells cure leukemia?Leukemia · 2026Review
- HIV tri-specific killer engagers directly enhance NK cell function and safely expand NK cells in vivo.Cell reports. Medicine · 2026Article
- Review
- Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy.Cancer cell international · 2026Review
- Review
- Depletion of the RNA-Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor microenvironment-driven natural killer cell diversity: mechanisms and therapeutic opportunities.Cancer biology & medicine · 2026Review
- Large-scale generation of iNK and CAR-iNK cells from CD34Nature biomedical engineering · 2026Article
- Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell-Derived NK Cell Therapies.Cell proliferation · 2026Review
- Enhancing CAR-NK persistence to unlock its full therapeutic potentials.Frontiers in immunology · 2026Review
- Natural Killer Cell Therapy in Ovarian Cancer: From Preclinical Potentials to Clinical Applications and Combination Strategies.International journal of biological sciences · 2026Review
- Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies.Frontiers in cell and developmental biology · 2026Review
- State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.International journal of molecular sciences · 2025Review
- Multiplexed iPSC platform for advanced NK cell immunotherapies.Cell reports. Medicine · 2025Review
- The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function.bioRxiv : the preprint server for biology · 2025Article
- CD16A Shedding Regulates Innate Cell Engager-Induced Serial Killing by Natural Killer Cells.European journal of immunology · 2025Article
- Unlocking antigen flexibility with widened patient access: CD3FR in off-the-shelf CAR T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- A novel CD3ε fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors at 4 institutions in 3 countries.
Karrune V WoanUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Hansol KimUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Ryan BjordahlFate Therapeutics, San Diego, CA 92121, USA.
Zachary B DavisUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Svetlana GaidarovaFate Therapeutics, San Diego, CA 92121, USA.
John GouldingFate Therapeutics, San Diego, CA 92121, USA.
Brian HancockFate Therapeutics, San Diego, CA 92121, USA.
Sajid MahmoodFate Therapeutics, San Diego, CA 92121, USA.
Ramzey AbujarourFate Therapeutics, San Diego, CA 92121, USA.
Hongbo WangUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Katie TuiningaUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Bin ZhangUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Cheng-Ying WuUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Behiye KodalUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Melissa KhawUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Laura BendzickUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Paul RogersFate Therapeutics, San Diego, CA 92121, USA.
Moyar Qing GeFate Therapeutics, San Diego, CA 92121, USA.
Greg BonelloFate Therapeutics, San Diego, CA 92121, USA.
Miguel MezaFate Therapeutics, San Diego, CA 92121, USA.
Martin FelicesUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA.
Janel HuffmanFate Therapeutics, San Diego, CA 92121, USA.
Thomas DaileyFate Therapeutics, San Diego, CA 92121, USA.
Tom T LeeFate Therapeutics, San Diego, CA 92121, USA.
Bruce WalcheckUniversity of Minnesota, Department of Veterinary and Biomedical Sciences, St. Paul, MN 55108, USA.
Karl J MalmbergKG Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Cancer Immunotherapy, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Bruce R BlazarUniversity of Minnesota, Department of Pediatrics, Minneapolis, MN 55455, USA.
Yenan T BrycesonBroegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway; Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Bahram ValamehrFate Therapeutics, San Diego, CA 92121, USA.
Jeffrey S MillerUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA. Electronic address: mille011@umn.edu.
Frank CichockiUniversity of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA. Electronic address: cich0040@umn.edu.
University of Minnesota · USFate Therapeutics (United States) · USKarolinska University Hospital · SEOslo University Hospital · NO
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MImplementing and Sustaining Innovations in Criminal Justice-DATS 2 (TCU RC)U01DA016190 · NIDA · TEXAS CHRISTIAN UNIVERSITY · PI KNIGHT, KEVIN · 2002 to 2012
$6.9MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MViral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2MIn Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4MExpression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killingR01CA203348 · NCI · UNIVERSITY OF MINNESOTA · PI WALCHECK, BRUCE K, WU, JIANMING · 2016 to 2025
$4.4MMolecular Programming of Immunological Memory in Human Natural Killer CellsR00HL123638 · NHLBI · UNIVERSITY OF MINNESOTA · PI CICHOCKI, FRANK · 2017 to 2019
$736kNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS R01 CA203348NCI NIH HHS R35 CA197292NHLBI NIH HHS R00 HL123638NHLBI NIH HHS R01 HL118979NIAID NIH HHS R37 AI034495
Abstract
Select subsets of immune effector cells have the greatest propensity to mediate antitumor responses. However, procuring these subsets is challenging, and cell-based immunotherapy is hampered by limited effector-cell persistence and lack of on-demand availability. To address these limitations, we generated a triple-gene-edited induced pluripotent stem cell (iPSC). The clonal iPSC line was engineered to express a high affinity, non-cleavable version of the Fc receptor CD16a and a membrane-bound interleukin (IL)-15/IL-15R fusion protein. The third edit was a knockout of the ecto-enzyme CD38, which hydrolyzes NAD
Indexed as
Induced Pluripotent Stem CellsNeoplasmsCells, CulturedHumansImmunotherapyImmunotherapy, AdoptiveKiller Cells, Naturalacute myeloid leukemiaadaptiveimmunotherapyinduced pluripotent stem celliPSCmultiple myelomanatural killer cellNK celloff-the-shelf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.